Introduction: The immune microenvironment of highgrade neuroendocrine carcinoma of the lung, including programmed death ligand 1 (PD-L1) expression, has not been well characterized.
Introduction
Neuroendocrine tumors of the lung represent a wide spectrum of morphologic types, ranging from typical carcinoids with a low malignant potential to SCLC, which displays the most rapid and disseminated growth. Although large cell neuroendocrine carcinoma (LCNEC) is categorized as a variant of the large cell carcinoma in NSCLC, the biological behaviors of LCNEC resemble those of SCLC. 1 Both LCNEC and SCLC are recognized as high-grade neuroendocrine carcinoma (HGNEC) of the lung and account for approximately 15% of all lung cancer cases. Patients with HGNEC have poor survival outcomes despite initial multimodal treatment including surgery, radiation, and chemotherapy.
Given the scarcity of therapeutic advances in HGNEC, the promise of immunotherapy for this disease has been growing. The high frequency of somatic mutations associated with cigarette smoking in SCLC, [2] [3] [4] [5] along with the presence of autoimmune paraneoplastic syndromes, suggests that SCLC is an immunogenic tumor. Interestingly, patients with SCLC with Lambert-Eaton Syndrome, which results from an immune response directed against specific antigens expressed on both SCLC and normal nerve cells, tend to have a better prognosis, perhaps because the immune response generated against the nervous system is also targeting tumor cells (TCs). 6 Furthermore, recent data suggest that smoking-related lung cancers with a high mutation load may be particularly sensitive to immunotherapy because of the formation of neoantigens. 7 SCLC and LCNEC possess an extremely high mutation rate of 7.4 and 10.5 proteinchanging mutations per million base pairs, respectively, 2, 8, 9 and the high mutation load led to immunotherapy trials in HGNEC patients. Along with the high mutation burden, 10 certain genetic aberrations are associated with immune evasion. Phosphatase and tensin homolog (PTEN) mutation was associated with decreased T-cell infiltration and resistance to immune checkpoint inhibitor therapy in malignant melanoma.
11
Recent genomic analysis revealed that PTEN mutation occurs up to 10% of SCLC cases. [2] [3] [4] [5] Programmed cell death protein 1 (PD-1) and its two ligands, namely, programmed death ligand 1 (PD-L1) and programmed death ligand 2, negatively regulate immune responses and can consequently lead to immune escape. Many studies have shown that cancer microenvironment manipulates the PD-L1/PD-1 axis and that induction of PD-L1 expression on TCs leads to the inhibition of effector T-cell activity.
12, 13 Accumulating evidence has indicated that PD-L1 expression is associated with clinicopathologic and immunologic factors in many human malignancies, including head and neck, breast, pancreas, lung, kidney, ovary, and blood cancers. 14, 15 However, only a few studies have examined the expression profile of PD-L1 and its clinical impact in pulmonary HGNEC. [16] [17] [18] [19] [20] [21] [22] [23] The purpose of this retrospective study was to determine the expression of PD-L1 on both TCs and immune cells (ICs) in the tumor microenvironment from a cohort of patients with SCLC and LCNEC. We also aimed to evaluate the association between the PD-L1 status, PTEN status, mutation burden measured by targeted deep sequencing and clinical features, including survival outcomes in patients with HGNEC of the lung.
Materials and Methods

Patients
A total of 192 patients with HGNEC of the lung who received treatment between March 2001 and April 2014 at the National Cancer Center of Korea were enrolled in this study. Histologic type was determined according to the 2004 WHO classification of lung tumors. Neuroendocrine differentiation in tumors was confirmed by using immunohistochemistry (IHC) markers such as chromogranin, synaptophysin, and neural cell adhesion molecule (CD56). TNM staging was based on the seventh edition of the lung cancer staging system. Recurrences or metastases were confirmed by using chest computed tomography, brain magnetic resonance imaging, and bone scan, as well as ultrasound and/or computed tomography scan of the abdomen. The comorbidity score was calculated from the Charlson comorbidity index. This study has been approved by the Ethics Committee of the National Cancer Center (NCC2014-0156).
IHC Analysis of PD-L1 Expression
An IHC method using the anti-PD-L1 and anti-PTEN antibodies was developed at Ventana Medical Systems (Tucson, AZ). Sections (5 mm) were cut from formalinfixed, paraffin-embedded blocks. Testing was performed using the human B7-H1/PD-L1 antibody (R&D Systems, Minneapolis, MN) and the PTEN mouse monoclonal antibody (Clone 28H6, NCL-PTEN, Novocastra Laboratories, United Kingdom) on the Benchmark XT platform with Cell Conditioning 1 for 64 minutes followed by preperoxidase inhibition and primary antibody incubation for 16 minutes at 37 C. The OptiView DAB IHC Detection Kit (Ventana Medical Systems) was used to detect protein expression. Tissue samples were counterstained with Mayer's hematoxylin and bluing reagent for 4 minutes.
Tumor cores were independently assessed by two observers (S. J. N. and G. K. L.) who were blinded to clinicopathologic data. Two independent pathologists (J. H. L. and G. K. L.) assessed the PD-L1 protein expression according to previously reported methodology. 24 
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Mutation Analysis
Genomic DNA was used for multiplex polymerase chain reaction with a panel covering 409 cancer-related genes. Libraries were generated using Ion AmpliSeq Comprehensive Cancer Panel (ThermoFisher Scientific, Waltham, MA) according to the manufacturer's recommendations. This panel consists of approximately 16,000 primer pairs covering 409 genes with known cancer associations. A total of 10 ng of genomic DNA from each sample was used to prepare barcoded libraries using IonXpress barcoded adapters (ThermoFisher). Libraries were combined to a final concentration of 3 ng/mL by using the Ion Library Quantification Kit (ThermoFisher Scientific), and emulsion polymerase chain reaction was performed by using the Ion Torrent OneTouchTM 2 System. Samples were sequenced on the Ion Proton sequencer (ThermoFisher) using Ion P1 chips. Sequencing reads were aligned to the 409 genes based on the Human Genome version 19 using Sequence Pilot version 4.2.0. Read depth and uniformity of coverage across individual amplicons were also assessed.
Bioinformatics analysis was performed as previously described with modification. 26 After a successful sequencing reaction, the raw signal data were analyzed with Torrent Suite (v3.4.2). The pipeline includes signal processing, quality score assignment, adapter trimming, read alignment to human genome 19 reference, mapping quality control, and coverage analysis. After completion of the first data analysis, lists of detected sequence variants (single-nucleotide variations and indels) were compiled in a variant call file format using the Genome Analysis Toolkit (v2.3.9Lite, Broad Institute, Cambridge, MA). Variant calls were further analyzed by using internally developed software that allows variant filtering.
Subsequent data filtering was performed by excluding variants with fewer than 25 reads, less than 5% allele frequency, and a quality score of 30000 or lower. To minimize the contamination of germline mutations, variants were filtered with a normal population variant database, The Korean Personal Genomes Project (http://opengenome.net/) 27 and Single-Nucleotide Polymorphism database. Additionally, high background noises were removed if they were recognizable as artifacts. Single-nucleotide variations and indels were annotated by using SnpEff (v4.1a) to classify variants as synonymous, nonsynonymous (NS), missense, or frameshift point mutations and frameshift indels. Additionally, the University of California Santa Cruz Genome Browser and Catalogue of Somatic Mutations in Cancer, version 67, were annotated to the final output. To compare the mutation burden, the total numbers of NS mutations were counted.
Genomic Analysis according to PTEN Status
To understand genomic aberration according to PTEN status, Fisher's exact test was performed for any NS mutation in each gene by PTEN status. A p value less than 0.05 was considered significant difference in mutational frequency. Rank metric was calculated by negative log2 p values. Gene set enrichment analysis for Kyoto Encyclopedia of Genes and Genomes pathway analysis was performed by the rank metricsorted list of genes, by using the GenePattern public server (http://software.broadinstitute.org/ cancer/software/genepattern/).
Statistical Analysis
Fisher's exact test was used to evaluate the relationships among PD-L1 expression, PTEN expression, and patient characteristics. The Mantel-Haenszel test and Cox regression models were applied to control for confounders. Mann-Whitney U tests were used to compare the difference in mean mutational load between patients with varying PD-L1 expressions. Survival curves, with survival calculated until death or last follow-up, were calculated using the Kaplan-Meier method. Multivariate analysis was performed using the Cox regression model. Statistical analysis was performed with SPSS 18 software (SPSS Inc., Chicago, IL). A p value less than 0.05 was considered statistically significant.
Results
Patient Characteristics
The characteristics of the study population stratified by histologic type are summarized in Table 1 . Of the 192 patients included in this study, 120 patients (62.5%) had cancer diagnosed as SCLC and 72 patients (37.5%) had their cancer diagnosed as of LCNEC. The median age of the patients at diagnosis was 66 years (range 36-89 years). Most patients were male (90.6%) and eversmokers (80.7%). Many patients (81.8%) had several comorbidities before diagnosis of their lung cancer (represented by a Charlson comorbidity score of !5).
The median age at diagnosis, sex distribution, and amount of cigarette smoking in ever-smokers did not vary significantly when patients were categorized according to histologic type. However, the proportion of never-smokers was higher in patients with SCLC (25.0%) than in patients with LCNEC (9.7%). Compared with patients with LCNEC, patients with SCLC had poorer performance status and had their lung cancer diagnosed at a more advanced stage. Frontline treatment for tumor varied with histologic type and stage. were more common than a score of IC1 (6.3%, [12 of 192] ). The incidence of overlapping PD-L1 expression on both TCs and ICs was low, and it decreased with increasing PD-L1 expression cutoffs (i.e., 5.7% of tumors were in both the TC1, TC2, or TC3 and IC1, IC2, or IC3 groups, 2.1% of tumors were in both the TC2/3 and IC 2/3 groups, and no tumors were in both the T3 and IC3 groups). In all PD-L1 expression cutoffs, there was a cohort in which PD-L1 expression was observed on either only TCs (TC1, TC2, or TC3 and IC0 in 9.4% [18 of 192] ) or ICs (TC0 and IC1, IC2, or IC3 in 25.5% [49 of 192] 
PD-L1 and PTEN Expression in Relation to
PD-L1 Expression and Survival
At the time of analysis, the median duration of follow-up was 80.7 months (range 31.1-183.4 months). The median progression-free survival (PFS) and overall survival (OS) times were 7.5 and 12.3 months, respectively. No relationship was noted between PD-L1 expression on TCs and survival (Fig. 3A) . On the other hand, patients with IC infiltration showed significantly longer PFS than did those without IC infiltration (median 11.3 versus 6.8 months [p < 0.01]) (Fig. 3B) . Patients with PD-L1 expression on ICs (IC1, IC2, or IC3) also had significantly longer PFS than those without PD-L1 expression on ICs (IC0) (median 11.3 versus 7.0 months [p ¼ 0.02]) (Fig. 3C) (Table 2) . Percentages in Venn diagrams represent the prevalence of PD-L1 expression in nonoverlapping subgroups. 
Nonsynonymous Mutation Burden and PD-L1 Expression
Of the 192 tumor samples consisting of formalinfixed, paraffin-embedded tissue, 102 were successfully analyzed with a matched IHC result. Targeted nextgeneration sequencing of 102 cases (39 LCNEC and 63 SCLC) identified a total of 2418 NS mutations in LCNEC samples and 2586 NS mutations in SCLC samples. Considering recent reports that mutational burden is a biomarker for immune checkpoint inhibitors, 7 the number of NS mutations per sample (range eight-999) was evaluated in relation to PD-L1 expression levels. PD-L1 expression on TCs was not related to NS mutation burden. However, IC infiltration and PD-L1 expression on ICs were positively correlated with NS mutation burden (p ¼ 0.05 and p ¼ 0.04, respectively) ( Table 4) . Tumors with PTEN loss showed significantly higher numbers of NS mutations than those that retained PTEN expression (p < 0.01). Other clinical factors, including a histologic difference between SCLC and LCNEC, smoking history, and stage, had no correlation with the number of NS mutations per samples.
Difference of Mutational Signature according to PTEN Status
Among 114 tumor samples that had PTEN IHC data, 102 samples matched targeted deep sequencing data. PTEN loss was detected in 10 out of 102 samples (9.8%). According to PTEN loss status, the frequency of genelevel mutation was analyzed. Among 328 annotated genes, mutational frequencies of 48 genes, including insulin receptor substrate 2 gene (IRS2), nuclear mitotic apparatus protein 1 gene (NUMA1), CREB regulated transcription coactivator 1 gene (CRTC1), myosin heavy chain 11 gene (MYH11), caspase recruitment domain family member 11 gene (CARD11), serine/threonine kinase 36 gene (STK36), phosphoinositide-3-kinase regulatory subunit 2 gene (PIK3R2), erb-b2 receptor tyrosine kinase 4 gene (ERBB4), and DNA methyltransferase 3 alpha gene (DNMT3A), were significantly higher in PTEN loss group (Fig. 4) . Interestingly, Kyoto Encyclopedia of Genes and Genomes pathway analysis using gene set enrichment analysis score clearly showed that mutational signature according to PTEN status indicated B-cell receptor signaling pathway, insulin signaling pathway, and chemokine signaling pathway (Fig. 5) .
Discussion
As therapeutic strategies that target the immune checkpoint axis have yielded clinical benefit in various types of cancers, characterizing the immunologic microenvironment of tumors has become important. The programmed death pathway defined by PD-L1 expression and infiltration of cytotoxic T cells is currently being evaluated to understand the immune context of tumors. Although PD-L1 expression has repeatedly correlated with a poor clinical outcome in several types of malignancy, other researchers have reported a lack of association 28, 29 or improved survival 30, 31 with PD-L1 expression. PD-L1 expression and the associated clinicopathologic characteristics have remained largely unknown in HGNEC of the lung. We have now examined PD-L1 expression by IHC in 192 specimens of SCLC and LCNEC.
PD-L1 expression on TCs was rarely observed in HGNEC specimens, and PD-L1 expression on TCs was not related to clinicopathologic covariates. Moderate infiltration of ICs was noted, most of which expressed PD-L1. Although previously reported tumor PD-L1 positivity with use of different cutoff values 18, 19, 21, 32 varies widely (from 0% to 83% [ Table 5 ]), several studies consistently reported a high rate of IC infiltration ranging from 48% to 94% in SCLC. 19, 21, 22 Because this discrepancy among studies is largely derived from unstandardized methods of PD-L1 IHC, 32 further comparative studies of PD-L1 detection methods are needed. Interestingly, we found that IC infiltration and PD-L1 expression on ICs were significantly decreased in tumors of the SCLC histologic type compared with in those of the LCNEC histologic type. Although the relationship between immunogenicity and tumor differentiation is controversial, [33] [34] [35] [36] the lower immune infiltration in SCLC than in LCNEC observed in our study may indicate one of the mechanisms by which immune editing occurs in HGNEC. 37 Even though caution is needed because of the interaction between sample quality and disease stage, IC infiltration decreased with advanced stage in our study, which is consistent with the results from previous studies. 16, 38 Recent reports have suggested a poor activity of cytotoxic T-lymphocyteassociated antigen 4 inhibition in patients with SCLC. 39, 40 Aside from rapid progression of disease that prevents sufficient exposure to the immunotherapeutic drugs, the decreased infiltration of ICs and PD-L1 expression on ICs in advanced stages observed in the current study suggest that ipilimumab monotherapy may not be effective in activating peripheral T cells in the tumor microenvironment in SCLC. Therefore, strategies to improve T-cell infiltration, such as combination of checkpoint inhibitors, 41 may allow for successful immunotherapy in patients with these diagnoses.
This study also found that IC infiltration and PD-L1 expression on ICs, were associated with a high NS mutation burden. An emerging theory stipulates that cancers with hypermutated phenotypes, such as NSCLC and malignant melanoma, are more likely to benefit from immune checkpoint blockade. [42] [43] [44] [45] Tumors typically have numerous types of somatic mutations, including NS mutations. Altered amino acid residues resulting from NS mutations can create new T-cell epitopes capable of eliciting an antitumor immune response. High mutation levels are also positively associated with the likelihood of immune-reactive missense mutations capable of inducing a CD8-positive antitumor immune response in a preclinical model, 46 and patients with a high mutational burden showed better response to immunotherapy. [47] [48] [49] However, studies focused on the correlation between mutation burden and the tumor immune microenvironment are limited. 10, 50 We have shown that IC infiltration and PD-L1 expression on ICs is enhanced in HGNEC tumors with a high mutation burden, supporting the theory that patients with this disease may be optimal candidates for immune modulation.
In addition to PD-L1 expression, genomic alterations plays a significant role in the immune responses to checkpoint inhibitors in melanoma. 11 We found that a small fraction of HGNEC tumors exhibit PTEN loss with correlating high mutation burden. However, PTEN status did not correlate with PD-L1 expression or immune infiltration. Considering the limited number of samples with PTEN loss, the relationship between PTEN expression and the immune signature needs to be resolved by examining larger numbers of samples.
In summary, we have demonstrated that PD-L1 expression is rarely observed in SCLC and LCNEC TCs. However, a substantial fraction of HGNEC samples showed IC infiltration and PD-L1 expression on ICs, and the IC infiltration and PD-L1 expression on ICs were lower in tumors of the SCLC histologic type than in those of the LCNEC histologic type. Additionally, IC filtration and PD-L1 expression on ICs were more frequent in samples with a higher mutation burden. Even though our study is limited by a relatively small number of patients and its retrospective design, our results are encouraging, considering the recent progress of immune checkpoint inhibitors being tested in SCLC. Because many clinical trials of PD-1 inhibitors are ongoing for SCLC, our findings can add insights regarding the predictive markers and treatment strategy for HGNEC.
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